Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Publication number: 20140303357Abstract: Disclosed is a method of preparing a stabilized liquid formulation of a protein drug, comprising admixing a protein drug with a composition for stabilization, wherein the composition for stabilization comprises a surfactant, a buffer, and a liquid medium, and has a pH from about 5 to about 8.Type: ApplicationFiled: March 31, 2014Publication date: October 9, 2014Applicant: Samsung Electronics Co., Ltd.Inventors: In Hwan LIM, Dong Uk Kim, Geun Woong Kim, Hee Kyung Sung, Yun Ju Jeong
-
Publication number: 20140302517Abstract: Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.Type: ApplicationFiled: April 2, 2014Publication date: October 9, 2014Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: SOO YEON JUNG, YUN JEONG SONG, MI YOUNG CHO, HAN NA CHOI
-
Patent number: 8853364Abstract: PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: September 17, 2009Date of Patent: October 7, 2014Assignee: Agensys, Inc.Inventors: Wangmao Ge, Pia M. Challita-Eid, Arthur B. Raitano, Aya Jakobovits
-
Patent number: 8852592Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.Type: GrantFiled: May 10, 2012Date of Patent: October 7, 2014Assignee: Biocare Medical, LLCInventors: Weimin Qi, David Tacha
-
Patent number: 8853369Abstract: The invention provides anti-Axl antibodies and methods of using the same.Type: GrantFiled: December 7, 2012Date of Patent: October 7, 2014Assignee: Genentech, Inc.Inventors: Lin Pei, Yan Wu, Xiaofen Ye
-
Publication number: 20140294841Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: ApplicationFiled: April 2, 2012Publication date: October 2, 2014Applicants: EUREKA THERAPEUTICS, INC., MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David A. Scheinberg, Tao Dao, Cheng Liu, Su Yan
-
Patent number: 8846872Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.Type: GrantFiled: November 18, 2010Date of Patent: September 30, 2014Assignee: MannKind CorporationInventors: Nathalie Kertesz, Sutao Zhu, Chih-Sheng Chiang
-
Patent number: 8841422Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.Type: GrantFiled: February 23, 2012Date of Patent: September 23, 2014Assignee: University of Maryland, BaltimoreInventors: Yun Qiu, Zhiyong Guo, Xi Yang
-
Patent number: 8834875Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.Type: GrantFiled: January 13, 2011Date of Patent: September 16, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventor: Edward Thein Htun Van Der Horst
-
Patent number: 8835608Abstract: An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells expression the MRP3 antigen, as well as kits, nucleic acids, polypeptides, and cells for providing the antibodies.Type: GrantFiled: November 30, 2007Date of Patent: September 16, 2014Assignee: Duke UniversityInventors: Chien-Tsun Kuan, Darell D Bigner
-
Patent number: 8828717Abstract: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.Type: GrantFiled: November 15, 2010Date of Patent: September 9, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey Schlom, Eduardo A. Padlan, Rafia Mehdi Kashmiri
-
Patent number: 8821880Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: GrantFiled: September 9, 2009Date of Patent: September 2, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Patent number: 8815240Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: GrantFiled: March 18, 2009Date of Patent: August 26, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20140234317Abstract: Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided.Type: ApplicationFiled: May 4, 2012Publication date: August 21, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Matthew David Onsum, Clet Niyikiza, Victor Moyo, William Kubasek, Akos Czibere
-
Patent number: 8809507Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: GrantFiled: December 7, 2009Date of Patent: August 19, 2014Inventor: Vuong Trieu
-
Publication number: 20140228546Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.Type: ApplicationFiled: June 14, 2012Publication date: August 14, 2014Applicant: Ablynx N.V.Inventors: Bruno Dombrecht, Peter Schotte, Cedric Josef Neotere Ververken
-
Publication number: 20140227258Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: March 14, 2014Publication date: August 14, 2014Applicant: Genentech, Inc.Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
-
Patent number: 8802826Abstract: Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: November 24, 2010Date of Patent: August 12, 2014Assignees: Alethia Biotherapeutics Inc., National Research Council of CanadaInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8796426Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.Type: GrantFiled: November 13, 2008Date of Patent: August 5, 2014Assignee: Philogen S.p.A.Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
-
Patent number: 8795661Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: May 20, 2013Date of Patent: August 5, 2014Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Patent number: 8795666Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: GrantFiled: February 7, 2013Date of Patent: August 5, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
-
Patent number: 8784821Abstract: The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.Type: GrantFiled: May 26, 2004Date of Patent: July 22, 2014Assignee: Amgen Research (Munich) GmbHInventors: Peter Kufer, Tobias Raum, Meera Berry, Roman Kischel, Susanne Mangold, Eva Krinner, Birgit Kohleisen, Steven Zeman, Christian Itin, Patrick Bäuerle
-
Patent number: 8771690Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: GrantFiled: October 29, 2013Date of Patent: July 8, 2014Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8772459Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.Type: GrantFiled: December 2, 2010Date of Patent: July 8, 2014Assignee: ImaginAb, Inc.Inventors: David Ho, Tove Olafsen, Arye Lipman
-
Patent number: 8758756Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.Type: GrantFiled: September 12, 2012Date of Patent: June 24, 2014Assignee: Industrial Technology Research InstituteInventors: Hsiang-Ching Wang, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
-
Patent number: 8758753Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.Type: GrantFiled: March 19, 2009Date of Patent: June 24, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Publication number: 20140170668Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.Type: ApplicationFiled: February 14, 2014Publication date: June 19, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Raghida BUKHALID, Ulrik NIELSEN, Shannon WERNER, Jeffrey David KEARNS
-
Patent number: 8753829Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: GrantFiled: December 4, 2012Date of Patent: June 17, 2014Assignee: Alper Biotech, LLCInventor: Özge Alper
-
Patent number: 8748580Abstract: T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.Type: GrantFiled: March 31, 2011Date of Patent: June 10, 2014Assignee: Immunovative Therapies, Ltd.Inventor: Michael Har-Noy
-
Patent number: 8747857Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: November 3, 2003Date of Patent: June 10, 2014Assignee: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Patent number: 8741594Abstract: The present invention relates to mitochondrial protein that can be used as a marker for diagnosing stomach cancer. According to the present invention, the marker for diagnosing stomach cancer comprises mitochondrial enoyl coenzyme A hydratase 1.Type: GrantFiled: January 17, 2008Date of Patent: June 3, 2014Assignee: Inje University Industry-Academic Cooperation FoundationInventors: Won Sun Park, Jae-Hong Ko, Na Ri Kim, Jin Han, Hyoung Kyu Kim, Mohamad Warda
-
Patent number: 8735552Abstract: The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: March 10, 2010Date of Patent: May 27, 2014Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Tatsuhiro Harada
-
Publication number: 20140134170Abstract: Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: March 12, 2012Publication date: May 15, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Gavin Macbeath, Victor Moyo
-
Patent number: 8722350Abstract: The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data.Type: GrantFiled: May 31, 2012Date of Patent: May 13, 2014Assignee: Case Western Reserve UniversityInventor: Sanford D. Markowitz
-
Patent number: 8722043Abstract: The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumor cell apoptosis in the context of an anticancer treatment.Type: GrantFiled: August 26, 2009Date of Patent: May 13, 2014Assignees: Diaclone, EFS Bourgogne Franche Comte, Universite de Franche ComteInventors: Christophe Borg, John Wijdenes, Camille Grandclement
-
Publication number: 20140127211Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: November 6, 2013Publication date: May 8, 2014Applicant: Pfizer Inc.Inventors: Kenneth G. Geles, Yijie Gao, Puja Sapra, Lioudmila Gennadievna Tchistiakova, Bin-Bing Stephen Zhou
-
Patent number: 8710194Abstract: The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. The single-chain variable fragment is able to recognize and specifically and selectively bind the epitope of the extracellular domain of CD99 human protein expressed on Ewing sarcoma cells. The fragment can thus be used for the diagnosis and 10 treatment of Ewing sarcoma.Type: GrantFiled: November 12, 2010Date of Patent: April 29, 2014Assignee: Istituto Ortopedico RizzoliInventors: Piero Picci, Katia Scotlandi, Alessandro Ascione, Maurizio Cianfriglia, Maria Luisa Dupuis, Michela Flego, Mara Gellini, Alessandra Mallano
-
Patent number: 8703920Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.Type: GrantFiled: November 9, 2009Date of Patent: April 22, 2014Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
-
Patent number: 8703132Abstract: The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: May 25, 2010Date of Patent: April 22, 2014Assignee: Hoffmann-La Roche, Inc.Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
-
Patent number: 8703143Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.Type: GrantFiled: August 21, 2007Date of Patent: April 22, 2014Assignee: Philogen S.p.A.Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
-
Patent number: 8697079Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).Type: GrantFiled: February 14, 2012Date of Patent: April 15, 2014Assignees: Quest Pharma Tech Inc., The Regents of the University of CaliforniaInventors: Manuel L. Penichet, Birgit C. Schultes, Christopher F. Nicodemus, Tracy R. Daniels, Gustavo Helguera, Jose A. Rodriguez
-
Patent number: 8697073Abstract: Disclosed are: an anti-podoplanin antibody which has a high binding activity and a high effector activity and has low antigenicity in humans or mice; and others. Specifically disclosed are: a chimeric antibody comprising an anti-podoplanin antibody for which an epitope is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 (excluding rat NZ-1 antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:3), and a heavy chain complementarity determining region and a light chain complementary determining region of the anti-podoplanin antibody; and others.Type: GrantFiled: September 30, 2010Date of Patent: April 15, 2014Assignee: Fujifilm RI Pharma Co., Ltd.Inventors: Yukinari Kato, Mika Kato, Yasuhiko Nishioka
-
Patent number: 8691952Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.Type: GrantFiled: December 29, 2006Date of Patent: April 8, 2014Assignee: Merck Patent GmbHInventors: Michael Super, Jonathan Davis, Pascal André Stein
-
Patent number: 8685656Abstract: This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an anti-body to a GABAB receptor. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to a GABAB receptor and treating a tumor associated with the disease.Type: GrantFiled: September 29, 2010Date of Patent: April 1, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: Josep Dalmau
-
Patent number: 8685399Abstract: The present invention relates to anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein thereof, which is capable of specific binding to an epitope located within the C-terminal fragment of human PAX 5 protein, wherein said epitope comprises from 3 to 17 amino acid residues of amino acid sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also relates to immunogenic peptide sequences for the production of the antibodies, diagnostic and therapeutic applications comprising using the antibodies and formulations comprising thereof.Type: GrantFiled: June 25, 2009Date of Patent: April 1, 2014Assignee: Dako Denmark A/SInventors: Kirsten Damgaard Hoff, Jakob O. Gjørret, Kurt Pii, Sussie Steen Jensen, Henrik Winther
-
Patent number: 8680243Abstract: Antibodies that bind to a GPR49 protein and have cell proliferation inhibitory activity against cells expressing the GPR49 protein are disclosed. Cell proliferation inhibitory activities are cytotoxic activities such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Pharmaceutical compositions, cell-proliferation inhibitors, and anticancer agents containing an antibody of the present invention as an active ingredient are also disclosed. Examples of cancer include gastric cancer, colon cancer, hepatocellular carcinoma, lung cancer, prostate cancer, ovarian cancer, Ewing's sarcoma, and glioma. Furthermore, methods for diagnosing cancer by detecting expression of a GPR49 protein or a gene encoding a GPR49 protein, and diagnostic agents and kits to be used in these methods are also disclosed.Type: GrantFiled: November 14, 2008Date of Patent: March 25, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Shinichi Funahashi
-
Patent number: 8673303Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: August 19, 2011Date of Patent: March 18, 2014Assignee: Biogen Idec MA Inc.Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
-
Publication number: 20140065150Abstract: Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 receptor (sFlt-1) antibody bound to a solid support in order to reduce blood levels of sFlt-1. Further disclosed are the sequences of the heavy chain and light chain CDRs of the anti-sFlt-1 antibodies.Type: ApplicationFiled: February 7, 2012Publication date: March 6, 2014Applicant: AGGAMIN PHARMACEUTICALS, LLCInventors: Paul Kussie, Woo S. Joo